Condition: Atopic Dermatitis · Sponsor: Sanofi
Interested? Contact the study team ↓
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
The objective of the study is to describe the therapeutic management of patients more than or equal to 18 years old eligible for systemic therapy or treated by systemic therapy for atopic dermatitis (AD). This study will be proposed to a sample of French dermatologists experienced in the management of AD, practicing in hospital centers and/or office-based dermatologists. The study will be conducted in real conditions of practice, systemic treatment decisions will be taken at the sole initiative of the participating physician irrespective of the patient enrollment decision. Each patient will be followed-up in routine care setting for 1 year.
This description comes directly from the study's public registry record.
Trial Transparency email recommended (Toll free for US & Canada) · 800-633-1610 · Contact-US@sanofi.com
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Signed informed consent form. * Patient with moderate to severe AD according to the Investigator's judgment and 1. Patient eligible to systemic treatment as Atopic Dermatitis Control Tool (ADCT) more than or equal to (≥) 7 and/or use topical corticosteroids (TCS) more than (\>) 90 gram (g)/month and/or TCS are not advisable. or 2. Patient currently under systemic treatment. * Able to understand and complete study-related questionnaires. Exclusion Criteria: * Any condition that, in the opinion of the Investigator, may interfere with patient's ability to participate in the study, such as short life expectancy, substance abuse, severe cognitive impairment, or other comorbidities that can predictably prevent the patient from adequately completing, as per routine care, the schedule of visits and assessments * Patient receiving systemic therapy only for a disease other than AD. * Patient participating in any interventional clinical trial at the time of enrolment. * Patient is under tutorship or curatorship; patient under safeguard of justice or deprived of his/her liberty by an administrative or court decision The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Investigational Site Number: 2500051 | Aix-en-Provence, France | Recruiting |
| Investigational Site Number: 2500023 | Amiens, France | Recruiting |
| Investigational Site Number: 2500004 | Angers, France | Recruiting |
| Investigational Site Number: 2500017 | Angers, France | Recruiting |
| Investigational Site Number: 2500050 | Arès, France | Recruiting |
| Investigational Site Number: 2500063 | Arès, France | Recruiting |
| Investigational Site Number: 2500054 | Bayonne, France | Recruiting |
| Investigational Site Number: 2500043 | Bezannes, France | Recruiting |
| Investigational Site Number: 2500040 | Biarritz, France | Recruiting |
| Investigational Site Number: 2500036 | Bordeaux, France | Recruiting |
| Investigational Site Number: 2500053 | Bordeaux, France | Recruiting |
| Investigational Site Number: 2500013 | Chalon-sur-Saône, France | Recruiting |
+ 50 more locations — full list on the registry record.
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.